Follow us on  LinkedFit for Health LinkedIN

Clinical Trials Phase 2

Question details: 
What would happen, if a Phase 2 is funded, but the company owning the drug candidate decides afterwards to develop the program further through Phase 3 to market (and thus does no longer comply with the 36-months-to-market dogma)?
Answer: 

Not reaching this goal will most probably have negative effects for the evaluation of the FTI instrument, but there will be no penalty for the consortium.